Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes

Expert Opinion on Investigational Drugs

Volumn 18, Issue 6, 2009, Pages 835-838

  Rungby, Joørgen ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

BI 1356; Dipeptidyl peptidase 4; GLP 1; ONDERO; Type 2 diabetes

Indexed keywords

8 (3 AMINO 1 PIPERIDINYL) 7 (2 BUTYNYL) 3 METHYL 1 (4 METHYL 2 QUINAZOLINYLMETHYL)XANTHINE; ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

ABSENCE OF SIDE EFFECTS; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; IC 50; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; REVIEW;

ANIMALS; ANTIGENS, CD26; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUGS, INVESTIGATIONAL; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN-SECRETING CELLS; MOLECULAR STRUCTURE; PURINES; QUINAZOLINES;

EID: 67649600688     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780902953707     Document Type: Review

References (26)

1. Advance Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;24:2560-2572 (Pubitemid 351831357)
2. Holmann RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;15:1577-1589
3. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes. JAMA 2007;298:194-206
4. Moore KB, Saudek CD. Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus. Am J Ther 2008;15:484-491
5. Nauck MA. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Horm Metab Res 2004;36:2-8 (Pubitemid 40115910)
6. Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-744
7. Zander M, Madsbad S, Madsen J, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-830 (Pubitemid 34233752)
8. Lerche S, Soendergaard L, Rungby J, et al. No increased risk of hypoglycaemic episodes during 48 hours of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects. Clin Endocrinol (Oxf) 2008 [Epub ahead of print]
9. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 2007;30:1335-1343 (Pubitemid 46871135)
10. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006;60:1454-1470 (Pubitemid 44560347)
11. Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes. Potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005;54:2988-2994
12. Burkey BF, Hoffman PK, Hassiepen U, et al. Adverse effects of dipeptidyl peptidases 8 & 9 inhibition in rodents revisited. Diabetes Obes Metab 2008;10:1057-1061
13. Deacon CF, Hughes TE, Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 1998;47:764-769 (Pubitemid 28201806)
14. Ahren B, Simonsson E, Larsson H, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002;5:869-875
15. Chia CW, Egan JM. Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab 2008;93:3703-3716
16. Thomas L, Eckhardt M, Langkopf E, et al. (R)-8-(3-amino-piperidin-1-yl)- 7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2, 6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 2008;325:175-182
17. Eckhardt M, Langkopf E, Mark M, et al. 8-(3-(R)-aminopiperidin-1-yl)-7- but-2-ynyl-3-methyl-1-(4-methyl-quinazolin- 2-ylmethyl)-3,7-dihydropurine-2,6- dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem 2007;50:6450-6453 (Pubitemid 350309082)
18. Dittberner S, Duval V, Staab A, et al. Determination of the absolute bioavailability of BI 1356 a substance with non linear pharmacokinetics using a population pharmacokinetic modeling approach [abstract 1110]. 16th Meet Popul Approach Group Eur (June 13, Copenhagen) 2008
19. Huttner S, Graefe-Mody EU, Withopf B, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol 2008;48:1171-1178
20. Graefe-Mody U, Padula SJ, Dugi KA, et al. The novel DPP-4 inhibitor BI 1356 (Proposed radename ONDERO) and metformin can be safely co-administered without dose adjustment. Diabetes 2008;57:A164
21. Thomas L, Tadayyon M, Mark M. Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but- 2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-yl methyl)-3,7-dihydro-purine-2,6- dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models. J Pharmacol Exp Ther 2009;328:556-563
22. Thomas L, Himmelsbach F, Eckhardt M, et al. BI 1356, a novel and selective xanthine based DPP-IV inhibitor, exhibits a superior profile when compared to sitagliptin and vildagliptin. Diabetologia 2007;50:S363
23. Sesoko S, Nakajima M, Hayashi N, et al. Safety, Tolerability and pharmacodynamics of single and multiple oral doses of the dipeptidyl peptidase 4 inhibitor BI 1356 in healthy Japanese volunteers. Diabetes 2008;57:A159
24. Wang Y. BI-1356 - dipeptidyl-peptidase IV inhibitor, antidiabetic agent. Drugs Future 2008;33:1171-1178
25. Forst T, Uhlig-Laske B, Ring A, et al. The novel, potent, and selective DPP-IV inhibitor B1 1356 significantly lowers HbA1c after only 4 weeks of treatment in patients with type 2 diabetes. Diabetes 2007;56:A157-8
26. Heise T, Tiessen R, Hüttner, et al. Treatment with BI 1356, a novel and potent DPP-IV inhibitor, significantly reduces glucose excursions after an oGTT in patients with type 2 diabetes. Diabetes 2007;56:A156